Not provided
Not provided
Not provided
Not provided
Not provided
no subjects enrolled
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental | 750 mg of LIM-0705 BID for 14 days. Up to 20 subjects. |
|
| B | Placebo Comparator | Placebo BID for 14 days. Up to 10 subjects. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LIM-0705 | Drug | Oral solution 750 mg LIM 0705 BID for 14 days. |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the effect of LIM-0705 on glucose metabolism, lipid metabolism and renal function in subjects with impaired glucose tolerance |
| approx. 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of treatment emergent adverse events and pharmacokinetics of LIM-0705 and its major metabolite |
|
Not provided
Inclusion Criteria:
Males, age 18-70 years old
Measured waist circumference to hip circumference ratio >0.90
Body mass index (BMI) of 27 - 40 kg/m2
Screening and Day -1 capillary glucose measurement between 110-160 mg/dL (6.1-8.9 mmol/L) after a 12 hour fast
Screening and Day -1 OGTT with a 2 hour post-glucose measurement ≥140 mg/dL (7.8 mmol/L) after a 12 hour fast
Screening HbA1c > 6 and ≤ 7.5%
Subjects must be in reasonably good health as determined by pre-study medical history, physical examination, 12-lead ECG, and the following laboratory measures:
Willing to remain in confinement at the clinical study unit for up to 18 days/17 nights and to return to the unit as specified for additional assessments
Willing to consume only the food that is provided by the clinical study unit
Non-smokers or "social smokers" (defined as fewer than 5 cigarettes per week) willing to abstain from smoking for the duration of study
Willing to abstain from alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages
Able to read, understand and follow the study instructions
Agree to use of two effective methods of contraception
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Albert Frauman, MD | Nucleus Network | Study Director |
Not provided
| ID | Term |
|---|---|
| D018149 | Glucose Intolerance |
| ID | Term |
|---|---|
| D006943 | Hyperglycemia |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Oral solution placebo BID for 14 days. |
|
| approx. 1 month |